

(12) STANDARD PATENT

(11) Application No. AU 2001278522 B2

(19) AUSTRALIAN PATENT OFFICE

(54) Title
Use of triazinetrione sulfones for combating coccidiosis

(51) International Patent Classification(s)
C07D 251/34 (2006.01) **A61K 47/14** (2006.01)
A01N 25/04 (2006.01) **A61K 47/34** (2006.01)
A01N 43/64 (2006.01) **A61K 47/36** (2006.01)
A61K 9/10 (2006.01) **A61K 47/38** (2006.01)
A61K 31/53 (2006.01) **A61P 31/00** (2006.01)
A61K 47/02 (2006.01) **A61P 33/02** (2006.01)

(21) Application No: **2001278522** (22) Date of Filing: **2001.08.06**

(87) WIPO No: **WO02/14288**

(30) Priority Data

(31) Number **10040174** (32) Date **2000.08.17** (33) Country **DE**

(43) Publication Date: **2002.02.25**
(43) Publication Journal Date: **2002.05.23**
(44) Accepted Journal Date: **2007.03.22**

(71) Applicant(s)
Bayer Aktiengesellschaft

(72) Inventor(s)
Greif, Gisela;Heep, Iris;Mundt, Hans-Christian

(74) Agent / Attorney
Davies Collison Cave, 255 Elizabeth Street, Sydney, NSW, 2000

**(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG**

(19) Weltorganisation für geistiges Eigentum
Internationales Büro



(43) Internationales Veröffentlichungsdatum
21. Februar 2002 (21.02.2002)

PCT

(10) Internationale Veröffentlichungsnummer
WO 02/14288 A1

- (51) Internationale Patentklassifikation⁷:** **C07D 251/34, A61K 31/53, A61P 31/00**
- (21) Internationales Aktenzeichen:** PCT/EP01/09060
- (22) Internationales Anmelde datum:**
6. August 2001 (06.08.2001)
- (25) Einreichungssprache:** Deutsch
- (26) Veröffentlichungssprache:** Deutsch
- (30) Angaben zur Priorität:**
100 40 174.0 17. August 2000 (17.08.2000) DE
- (71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme von US):** **BAYER AKTIENGESELLSCHAFT [DE/DE]; 51368 Leverkusen (DE).**
- (72) Erfinder; und**
- (75) Erfinder/Anmelder (nur für US):** **GREIF, Gisela [DE/DE]; Marienhöhe 15, 53424 Remagen (DE). BILL, Iris [DE/DE]; Gertrudisstrasse 30, 50859 Köln (DE). MUNDT, Hans-Christian [DE/DE]; Lessingstrasse 30, 40699 Erkrath (DE).**
- (74) Gemeinsamer Vertreter:** **BAYER AKTIENGESELLSCHAFT; 51368 Leverkusen (DE).**
- (81) Bestimmungsstaaten (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Bestimmungsstaaten (regional):** ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), europäisches Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI-Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Veröffentlicht:

- mit internationalem Recherchenbericht
— insgesamt in elektronischer Form (mit Ausnahme des Kopfbogens); auf Antrag vom Internationalen Büro erhältlich

Zur Erklärung der Zwei buchstaben-Codes und der anderen Abkürzungen wird auf die Erklärungen ("Guidance Notes on Codes and Abbreviations") am Anfang jeder regulären Ausgabe der PCT-Gazette verwiesen.



WO 02/14288 A1

(54) Title: USE OF TRIAZINETRIONE SULFONES FOR COMBATING COCCIDIOSIS

(54) Bezeichnung: VERWENDUNG VON TRIAZINTRION-SULFONEN ZUR BEKÄMPFUNG VON COCCIDIOSEN

(57) Abstract: The invention relates to the use of a special derivative of triazinetriones for combating coccidiosis in animals, particularly pigs.

(57) Zusammenfassung: Die vorliegende Erfindung betrifft die Verwendung spezieller Derivate von Triazintronen zur Bekämpfung von Coccidiosen in Tieren, insbesondere Schweinen.

Use of triazinetrione sulphones for combating coccidiosis

The present invention relates to the use of specific derivatives of triazinetriones for controlling coccidioses in animals.

5

Coccidioses are infections which occur frequently in livestock and thus, for example, subclinical infections caused by protozoa of the genera coccidia, sarcosporidia and toxoplasma in pigs are spread worldwide. *Isospora suis* infections, for example, have, however, only in recent years been recognized as the cause of piglet diarrhoea and been researched very intensively. As a rule, infection takes place from the mother sow to the piglets or from piglet to piglet via oocysts each of which contain two sporocysts each with two sporozoites. The parasitic stages multiply in the epithelial cells of the villi of the small intestine, but extraintestinal stages have also been detected in the liver, spleen and lymph nodes. The clinical appearance of the disease includes a necrotic, inflammatory destruction of the intestinal epithelial cells and thus extensive interference with digestion and absorption. An acute disease is characterized by a watery, whitish or yellowish foul-smelling diarrhoea which usually occurs in week 2-3 of life. Infected piglets have a reduced weight gain. The treatment and therapy of the disease have not to date been adequately solved. Antibiotics are ineffective; although sulphonamides are recommended, therapy is usually too late. Other possibilities of treatment are contradictory: it was not possible to prevent disease by administering monensin, amprolium or furazolidone to experimentally infected piglets. In recent investigations it was possible to identify in some units, despite good hygiene, *Isospora suis* in up to 92% of all litters.

20

Other possibilities of treatment are contradictory: it was not possible to prevent disease by administering monensin, amprolium or furazolidone to experimentally infected piglets. In recent investigations it was possible to identify in some units, despite good hygiene, *Isospora suis* in up to 92% of all litters.

25

It is known from a number of publications, inter alia German Offenlegungsschriften 27 18 799, 25 090 37, 25 323 63, 24 137 22, WO 99/62519 that various derivatives of triazinetriones are suitable for controlling coccidioses in livestock.


30

It is also known from a number of publications, for example Driesen et al., Australian Vet. J., 72 (4) 139-141, 1995; Rommel et al., Int. J. of Parasit., 17, 639-647, 1987; Haberkorn and Mundt., Prakt. Tierarzt, 69 (4), 46, 49-51, 1988) that toltrazuril, a

particular triazinetrione derivative, is suitable for treating coccidiosis (*Isospora suis*) in pigs.

Because of the wide variety of requirements to be met by modern pharmaceuticals,
5 for example concerning level of activity, duration of action, spectrum of action, range
of applications, toxicity, combination with other active ingredients, combination with
formulation aids or synthesis, because of the possible occurrence of resistance, the
development of such substances cannot, however, ever be regarded as complete, and
there is a continuing great need for novel compounds which have advantages, at least
10 in some aspects, over known compounds.

It has now been found that triazinetrione sulphones of the formula (I)



15 in which

R^1 represents halogenoalkyl,

20 R^2 represents alkyl, alkoxy, halogen or $SO_2N(CH_3)_2$, and their physiologically tolerated salts, have a very good coccidiocidal effect together with astonishingly low mammalian toxicity.

The compounds of the formula (I) can be obtained by the processes disclosed in German Offenlegungsschriften 27 18 799, 25 090 37, 25 323 63, 24 137 22,
25 WO 99/62519.

5 The compounds of the formula (I) show when used according to the invention for treating coccidioses in animals a mammalian toxicity which is surprisingly low compared with compounds known in the state of the art, and are therefore clearly superior to the known compounds in this use.

Compounds of the formula (I) employed for the use in controlling coccidioses in livestock are preferably those

10 in which

R^1 represents C_1 - C_4 -halogenoalkyl with 1 to 5 halogen atoms,

15 R^2 represents C_1 - C_4 -alkyl, C_1 - C_4 -alkoxy, halogen or $SO_2N(CH_3)_2$, and their physiologically tolerated salts.

Compounds of the formula (I) particular preferably employed according to the invention are those in which

20 R^1 represents C_1 - C_4 halogenoalkyl with 1 to 5 halogen atoms,

R^2 represents C_1 - C_4 -alkyl, and their physiologically tolerated salts.

25 Compounds of the formula (I) very particularly preferably employed according to the invention are those in which


R^1 represents C_1 - C_4 perhalogenoalkyl,

R^2 represents methyl or ethyl, and their physiologically tolerated salts.

30

In particular, the use of the compound of the formula

5



10

with the name ponazuril is very particularly preferred.

As now claimed, according to one aspect the present invention provides use of compounds of the formula (I), in which R¹ represents halogenoalkyl, R² represents alkyl, alkoxy, 15 halogen or SO₂N(CH₃)₂, and their physiologically tolerated salts, for controlling coccidiosis caused by *Isospora suis* in an animal.

As now claimed, according to another aspect the present invention also provides a composition comprising a) compounds of the formula (I) in concentrations of from 0.1 to 20 30% by weight, b) suspension stabilizers such as, for example, bentonites and/or xanthans in concentrations each of from 0.01 to 5% by weight, c) optionally ionic or nonionic wetting agents concentrations of from 0.01 to 5% by weight, d) optionally antifoams based, for example, on silicones in concentrations of from 0.01 to 5% by weight, e) 25 optionally humectants in concentrations of from 1 to 30% by weight, f) optionally preservatives or else combinations thereof in concentrations of from 0.001 to 5% by weight, and g) optionally acidic or basic substances in the concentrations necessary to adjust the pH.

As now claimed, according to another aspect the present invention also provides use of 30 compounds of the formula (I) in which R¹ represents halogenoalkyl, R² represents alkyl, alkoxy, halogen or SO₂N(CH₃)₂, and their physiologically tolerated salts in the manufacture of a medicament for controlling coccidiosis caused by *Isospora suis* in an animal.

- 4A -

The compounds of the formula (I) may, where appropriate, depending on the nature and number of the substituents be in the form of geometric and/or optical isomers or regioisomers or mixtures of such isomers of varying composition. Both the use of the pure isomers and of the mixtures of isomers are claimed according to the invention.

5

Compounds which are preferred, particularly preferred or very particularly preferred etc. are those which have the substituents mentioned below as preferred, particularly preferred or very particularly preferred etc.

10

Preferred among the halogenoalkyl radicals indicated in the definition of R¹, including those mentioned as preferred, particularly preferred, very particularly preferred, are in each case in turn the fluoroalkyl radicals.

15

The radical definitions and explanations stated above in general or stated in preferred ranges can, however, also be combined as desired with one another, that is to say between the respective ranges and preferred ranges.

20

The compounds according to the invention can for the use according to the invention against coccidiosis be converted into all conventional formulations and be administered in various administration forms. Oral administrations are preferred in this connection, in particular administration as oral aqueous suspension.

Preferred dosages are 1-500 mg of active ingredient per kg of body weight of the animal to be treated, particularly preferred dosages are from 10 to 200 mg/kg and very particularly preferred dosages are 20-100 mg/kg.

5

Preparations suitable for animals are:

solutions such as solutions for injection, oral solutions, concentrates for oral administration after dilution, solutions for use on the skin or in body cavities, pour-on formulations, gels;

emulsions and semisolid preparations for oral or cutaneous use and for injection; examples of semisolid preparations are suspensions, pastes.

15 Formulations in which the active ingredient is processed in an ointment base or in an oil-in-water or water-in-oil emulsion base;

solid preparations such as powders, premixes or concentrates, granules, pellets, tablets, boluses, capsules; aerosols and inhalations.

20

Solutions for injection are administered intravenously, intramuscularly and subcutaneously.

25 Solutions for injection are prepared by dissolving the active ingredient in a suitable solvent and possibly adding additions such as solubilizers, acids, bases, buffer salts, antioxidants, preservatives. The solutions are sterilized by filtration or, if necessary, prepared aseptically and bottled.

30 Solvents which may be mentioned are: physiologically tolerated solvents such as water, alcohols such as ethanol, butanol, benzyl alcohol, glycerol, propylene glycol, polyethylene glycols, N-methylpyrrolidone, glycerol formal, solketal

(= isopropylideneglycerol), dimethylacetamide, 2-pyrrolidone, tetraglycol (= polyethylene glycol ether of tetrahydrofurfuryl alcohol) and mixtures thereof.

5 The active ingredients can, where appropriate, also be dissolved in physiologically tolerated vegetable or synthetic oils suitable for injection.

Solubilizers which may be mentioned are: solvents which promote the dissolving of the active ingredient in the main solvent or prevent its precipitation. Examples are polyvinylpyrrolidone, polyethoxylated castor oil, polyethoxylated sorbitan esters.

10

Examples of preservatives are: benzyl alcohol, trichlorobutanol, p-hydroxybenzoic esters, n-butanol, and organic acids with preserving properties such as benzoic acid, propionic acid or sorbic acid and salts thereof. The preservatives may, where appropriate, also be employed as combination of two or more agents.

15

Oral solutions are used directly. Concentrates are used orally after previous dilution to the use concentration. Oral solutions and concentrates are prepared as described above for injection solutions, it being possible to dispense with sterile operations.

20

Solutions for use on the skin or body cavities are poured on, painted on, rubbed in, sprayed on or used for dips. These solutions are prepared as described above for solutions for injection. It is particularly advantageous to add thickeners during preparation.

25

Thickeners are: inorganic thickeners such as bentonites, colloidal silica, aluminium monostearate, organic thickeners such as cellulose derivatives, polyvinyl alcohols and their copolymers, acrylates and methacrylates, xanthans.

30

Gels are applied to or spread on the skin or introduced into body cavities. Gels are prepared by mixing solutions which have been prepared as described for solutions for

injection with sufficient thickener to result in a clear composition with an ointment-like consistency. The thickeners applied are the thickeners indicated hereinbefore.

5 Pour-on formulations are poured or sprayed on to limited areas of the skin, in which case the active ingredient either penetrates through the skin and has a systemic action or is distributed on the surface of the body.

10 Pour-on formulations are prepared by dissolving, suspending or emulsifying the active ingredient in suitable solvents or mixtures of solvents which are compatible with skin. Further excipients such as colorants, absorption-promoting substances, 15 antioxidants, light stabilizers, adhesives are added where appropriate.

15 Solvents which may be mentioned are: water, alkanols, glycols, polyethylene glycols, polypropylene glycols, glycerol, aromatic alcohols such as benzyl alcohol, phenylethanol, phenoxyethanol, esters such as ethyl acetate, butyl acetate, benzyl benzoate;

20 Ethers such as alkylene glycol alkyl ethers such as dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, ketones such as acetone, methyl ethyl ketone, aromatic and/or aliphatic hydrocarbons, vegetable or synthetic oils, DMF, dimethylacetamide, N-methylpyrrolidone, 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane.

25 Colorants are all colorants which are approved for use on livestock and which can be dissolved or suspended.

Absorption-promoting substances are DMSO, spreading oils such as isopropyl myristate, dipropylene glycol pelargonate, silicone oils, fatty acid esters, triglycerides, fatty alcohols.

Antioxidants are sulphites or metabisulphites such as potassium metabisulphite, ascorbic acid, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol.

5 Examples of light stabilizers are substances from the class of benzophenones or novantisolic acid.

Examples of adhesives are cellulose derivatives, starch derivatives, polyacrylates, natural polymers such as alginates, gelatin.

10 Emulsions can be used orally, cutaneously or as injection.

Emulsions are either of the water-in-oil type or of the oil-in-water type.

15 They are prepared by dissolving the active ingredient in one phase and homogenizing the latter with the assistance of suitable emulsifiers and, where appropriate, further excipients such as colorants, absorption-promoting substances, preservatives, antioxidants, light stabilizers, viscosity-increasing substances.

20 Mention may be made of the following as hydrophobic phase (oils): paraffin oils, silicone oils, natural vegetable oils such as sesame oil, almond oil, castor oil, synthetic triglycerides such as caprylic/capric acid triglyceride, triglyceride mixture with vegetable fatty acids of chain length C₈₋₁₂ or other specially selected natural fatty acids, partial glyceride mixtures of saturated or unsaturated, possibly also hydroxyl group-containing fatty acids, mono- and diglycerides of C_{8/C₁₀}-fatty acids.

25 Fatty acid esters such as ethyl stearate, di-n-butyryl adipate, hexyl laurate, dipropylene glycol perlargonate, esters of a branched fatty acid of medium chain length with saturated fatty alcohols of chain length C_{16-C₁₈}, isopropyl myristate, isopropyl palmitate, caprylic/capric esters of saturated fatty alcohols of chain length C_{12-C₁₈}, isopropyl stearate, oleyl oleate, decyl oleate, ethyl oleate, ethyl lactate, waxy

fatty acid esters such as artificial duck preen gland oil, dibutyl phthalate, diisopropyl adipate, ester mixtures related to the latter inter alia.

5 Fatty alcohols such as isotridecyl alcohol, 2-octyldodecanol, cetylstearyl alcohol, oleyl alcohol.

Fatty acids such as, for example, oleic acid and mixtures thereof.

Mention may be made of the following as hydrophilic phase:

10 water, alcohols such as, for example, propylene glycol, glycerol, sorbitol and mixtures thereof.

Mention may be made of the following as emulsifiers: surfactants (including emulsifiers and wetting agents), such as

15 1. nonionic, for example polyethoxylated castor oil, polyethoxylated sorbitan monooleate, sorbitan monostearate, ethyl alcohol, glycerol monostearate, polyoxyethyl stearate, alkylphenol polyglycol ether,

20 2. ampholytic such as di-Na N-lauryl- β -iminodipropionate or lecithin,

3. anionic such as Na-lauryl sulphate, fatty alcohol ether sulphates, mono/dialkyl polyglycol ether orthophosphoric ester monoethanolamine salt,

25 4. cationic such as cetyltrimethylammonium chloride.

Further suitable excipients are:

viscosity-increasing and emulsion-stabilizing substances such as carboxymethyl-cellulose, methylcellulose and other cellulose and starch derivatives, polyacrylates, 30 alginates, gelatin, gum arabic, polyvinylpyrrolidone, polyvinyl alcohol, copolymers

of methyl vinyl ether and maleic anhydride, polyethylene glycols, waxes, colloidal silica or mixtures of the substances mentioned.

5 Suspensions can be used orally, cutaneously or as injection. They are prepared by suspending the active ingredient in a liquid vehicle where appropriate with addition of further excipients such as wetting agents, antifoams, colorants, absorption-promoting substances, suspension stabilizers, preservatives, antioxidants, light stabilizers, humectants.

10 Mention may be made as preferred of suspensions which can be administered orally and contain:

A) compounds of the formula (I) in concentrations of from 0.1 to 30% by weight, particularly preferably from 1 to 10% by weight.

15

B) suspension stabilizers such as, for example, bentonites and/or xanthans in concentrations each of from 0.01 to 5% by weight, particularly preferably from 0.05 to 1% by weight.

20 C) where appropriate ionic or nonionic wetting agents in concentrations of from 0.01 to 5% by weight, particularly preferably from 0.1 to 0.5% by weight.

25 D) where appropriate antifoams based, for example, on silicones in concentrations of from 0.01 to 5% by weight, particularly preferably from 0.05 to 0.5% by weight.

E) where appropriate humectants in concentrations of from 1 to 30% by weight, particularly preferably from 5 to 20% by weight.

- F) where appropriate preservatives or else combinations thereof in concentrations of from 0.001 to 5% by weight, particularly preferably from 0.1 to 0.5% by weight.
- 5 G) where appropriate acidic or basic substances in the concentrations necessary to adjust the pH.

Liquid vehicles which may be mentioned are the solvents and homogeneous mixtures of solvents mentioned hereinbefore as long as they are pharmaceutically acceptable
10 and the active ingredient or active ingredients dissolve therein to only a small extent or not at all. Water is preferably used.

Wetting agents (dispersants) which may be mentioned for the suspensions which can be administered orally are surfactants such as

- 15 1. anionic such as Na lauryl sulphate, fatty alcohol ether sulphates, mono/dialkyl polyglycol ether orthophosphoric ester monoethanolamine salt, ligninsulphonates or dioctyl sulphosuccinate,
- 20 2. cationic such as cetyltrimethylammonium chloride,
3. amphotolytic such as di-Na N-lauryl-β-iminodipropionate or lecithin,
- 25 4. nonionic, for example polyethoxylated castor oil, polyethoxylated sorbitan monooleate, sorbitan monostearate, ethyl alcohol, glycerol monostearate, polyoxyethylene stearate, alkylphenol polyglycol ether, Pluronic®.

Suitable antifoams are those based on silicones, for example dimethicone or simethicone.

Suspension stabilizers which can be employed are, for example, the viscosity-increasing substances mentioned hereinbefore.

5 It is possible to employ conventional humectants, and examples which may be mentioned are: propylene glycol, glycerol, sugar alcohols such as sorbitol, sugars such as sucrose.

10 Suitable preservatives are known to the skilled person; examples have already been mentioned hereinbefore. Organic acids with preserving properties are preferably employed, such as, for example, benzoic acid, propionic acid or sorbic acid and salts thereof. The preservatives can also be employed as combination of two or more agents, and a preferred example which may be mentioned is a combination of sodium propionate and sodium benzoate.

15 Suitable acidic or basic substances for adjusting the pH are conventional pharmaceutically acceptable acids, bases and buffers.

20 Acids which may be mentioned are, for example: hydrochloric acid, citric acid and tartaric acid. Examples of bases which may be mentioned are: alkali metal hydroxides such as sodium hydroxide and potassium hydroxide; alkali metal and alkaline earth metal carbonates such as sodium carbonate, and amines, for example mono-, di- or triethanolamine.

25 Examples of suitable buffer systems are those based on phosphates.

The pH is preferably in the range from 2 to 10, in particular 3 to 7.

30 The active ingredient is preferably employed in micronized form in the suspensions, normally in particle size distributions of from 0.1 to 100 μm , preferably 1 to 50 μm .

Further excipients which may be mentioned are those indicated hereinbefore.

Pastes can be administered orally or cutaneously. They differ from the mobile to viscous suspensions and emulsions described above by their higher viscosity. Pastes containing ponazuril (= toltrazuril sulphone) have already been described in
5 WO 99/62519.

Those which may be mentioned as preferred are pastes which can be administered orally and contain compounds of the formula (I), which are characterized in that

- 10 a) the active ingredient is present in a particle size of 1×10^{-6} m and a maximum particle size of 50×10^{-6} m in a concentration of 0.1 - 20% by weight,
- 15 b) polyacrylic acids with an acrylic acid content of from 56 to 68% by weight and a molecular weight of about 3×10^6 , which are neutralized with alkali metal or alkaline earth metal bases, are present in a concentration of 0.1 - 5% by weight,
- 20 c) where appropriate humectants are present in a concentration of from 5 to 30% by weight,
- d) where appropriate preservatives are present in a concentration of from 0.01 to 0.5% by weight,
- 25 e) and the remainder in 100% by weight is made up with water.

The active ingredient is present in the said pastes preferably in concentrations by weight of from 5% by weight to 20% by weight, particularly preferably from 10% by weight to 15% by weight.

- 30 The polyacrylic acids used in the said pastes are preferably neutralized with alkali metal hydroxide or carbonate. Polyacrylic acids are present in the formulation

according to the invention in concentrations by weight of from 0.2% to 1%, preferably of 0.5%. These are commercially available and known in pharmacopoeias for example under the proprietary name Carbomer 934 P.

5 Preferred preservatives in the said pastes are para-hydroxybenzoic esters (parabens) such as methyl 4-hydroxybenzoate, ethyl 4-hydroxybenzoate or propyl 4-hydroxybenzoate. The preservatives can be employed singly or in combination for adequate preservation. They are normally present in concentrations of 0.01 - 0.5% by weight.

10

It is optionally possible for the said pastes also to contain humectants such as, for example, glycerol or 1,2-propylene glycol. Humectants are employed in concentrations by weight of from 5% to 30%, preferably from 10% to 20%.

15 The active ingredient is present in the said pastes in a particle size of from 1 to 10×10^{-6} m, preferably from 1 to 5×10^{-6} m. The maximum of the particle size is 50×10^{-6} m, preferably 30×10^{-6} m. The particle sizes are determined by laser scattering measurement (for example with a Malvern Mastersizer). The paste is obtained by mixing the individual components. Its consistency can be altered by 20 increasing or decreasing the water content. A pasty consistency is desired. This permits oral administration of the composition with suitable applicators such as syringes, tubes, spatulas etc.

25 To prepare solid preparations, the active ingredient is mixed with suitable carriers, where appropriate with the addition of excipients, and converted into the desired shape.

Carriers which may be mentioned are all physiologically tolerated solid inert substances. Inorganic and organic substances are used as such. Examples of inorganic 30 substances are sodium chloride, carbonates such as calcium carbonate, hydrogen

carbonates, aluminium oxides, silicas, aluminas, precipitated or colloidal silicon dioxide, phosphates.

5 Examples of organic substances are sugars, cellulose, human and animal foods such as milk powder, animal meals, ground and crushed grains, starches.

Excipients are preservatives, antioxidants, colorants, which have already been mentioned hereinbefore.

10 Further suitable excipients are lubricants and glidants such as, for example, magnesium stearate, stearic acid, talc, bentonites, disintegration-promoting substances such as starch or crosslinked polyvinylpyrrolidone, binders such as, for example, starch, gelatin or linear polyvinylpyrrolidone, and dry binders such as microcrystalline cellulose.

15 The active ingredients can also be in the form of their encapsulated solid or liquid formulations mentioned above.

20 The active ingredients can also be used in the form of an aerosol. For this purpose, the active ingredient is finely dispersed in a suitable formulation under pressure.

It may also be advantageous to use the active ingredients in formulations which release the active ingredient in a delayed manner.

25 The active ingredients are preferably administered together with the feed and/or the drinking water.

30 The feed includes feedstuff ingredients of vegetable origin such as hay, beets, cereals, cereals by-products, feedstuff ingredients of animal origin such as meat, fats, dairy products, bone meal, fish products, also feedstuff ingredients such as vitamins, proteins, amino acids, for example DL-methionine, salts such as calcium carbonate

and sodium chloride. The feed also includes supplementary, formulated and compounded feedstuffs. These contain feed ingredients in a composition which ensures a balanced diet in terms of energy and protein supply and the supply of vitamins, mineral salts and trace elements.

5

The concentration of the active ingredients in the feed is normally about 0.01 to 500 ppm, preferably 0.1 to 50 ppm.

10 The active ingredients can be added as such or in the form of premixes or feed concentrates to the feed.

Premixes and feed concentrates are mixtures of the active ingredient with a suitable carrier.

15 The carriers include feedstuff ingredients or mixtures thereof.

They may additionally contain further aids such as, for example, substances which control the flow properties and mixing properties, such as, for example, silicas, bentonites, ligninsulphonates. It is additionally possible to add antioxidants such as 20 BHT or preservatives such as sorbic acid or calcium propionate.

Concentrates for administration via the drinking water must be formulated so that a clear solution or a stable homogeneous suspension is produced on mixing with the drinking water.

25

Suitable carriers are therefore water-soluble substances (feed additives) such as sugars or salts (for example citrates, phosphates, sodium chloride, Na carbonate).

They may likewise contain antioxidants and preservatives.

30

The active ingredients are suitable, while having a surprisingly low toxicity for warm-blooded species, for the control according to the invention of parasitic protozoa which occur in animal management and animal breeding among agricultural and breeding animals, including livestock animals bred for profit on farms, as well as zoo, laboratory and experimental animals and comparison animals such as pets. They are moreover effective against all or individual stages of development of the pests and against resistant and normally sensitive strains. Control of the parasitic protozoa is intended to reduce disease, deaths and reductions in performance (for example in the production of meat, milk, wool, hides, eggs, honey etc) so that more economic and easier animal management is possible through use of the active ingredients.

The parasitic protozoa include:

- Mastigophora (Flagellata) such as, for example, Trypanosomatidae, for example Trypanosoma brucei, T. gambiense, T. rhodesiense, T. congolense, T. cruzi, T. evansi, T. equinum, T. lewisi, T. percae, T. simiae, T. vivax, Leishmania brasiliensis, L. donovani, L. tropica, such as, for example, Trichomonadidae, for example Giardia lamblia, G. canis.
- 20 Sarcomastigophora (Rhizopoda) such as Entamoebidae for example Entamoeba histolytica, Hartmanellidae for example Acanthamoeba sp., Hartmanella sp.
- 25 Apicomplexa (Sporozoa) such as Eimeridae for example Eimeria acervulina, E. adenoides, E. alabahmensis, E. anatis, E. anseris, E. arloingi, E. ashata, E. auburnensis, E. bovis, E. brunetti, E. canis, E. chinchillae, E. clupearum, E. columbae, E. contorta, E. crandalis, E. debbiecki, E. dispersa, E. ellipsoidales, E. falciformis, E. faurei, E. flavescens, E. gallopavonis, E. hagani, E. intestinalis, E. iroquoina, E. irresidua, E. labbeana, E. leucarti, E. magna, E. maxima, E. media, E. meleagridis, E. meleagrimitis, E. mitis, E. necatrix, E. ninakohlyakimovae, E. ovis, E. parva, E. pavonis, E. perforans, E. phasani, E. piriformis, E. praecox, E. residua, E. scabra, E. spec., E. stiedai, E. suis, E. tenella, E. truncata, E. truttae,

E. zuernii, Globidium spec., Isospora belli, I. canis, I. felis, I. ohioensis, I. rivolta, I. spec., I. suis, Neospora caninum, N. hugesi, Cystisospora spec., Cryptosporidium spec. such as Toxoplasmadidae for example Toxoplasma gondii, such as Sarcocystidae for example Sarcocystis bovicanis, S. bovihominis, S. neurona, 5 S. ovicanis, S. ovifelis, S. spec., S. suis hominis such as Leucocystidae for example Leucocytozoon simondi, such as Plasmodiidae for example Plasmodium berghei, P. falciparum, P. malariae, P. ovale, P. vivax, P. spec., such as Piroplasmea for example Babesia argentina, B. bovis, B. canis, B. spec., Theileria parva, Theileria spec., such as Adeleina for example Hepatozoon canis, H. spec.

10

In addition Myxospora and Microspora, for example Glugea spec. Nosema spec.

In addition Pneumocystis carinii, and Ciliophora (Ciliata) such as, for example, Balantidium coli, Ichthiophthirius spec., Trichodina spec., Epistylis spec.

15

The compounds according to the invention are also effective against protozoa which occur as parasites on insects. Those which may be mentioned are parasites of the phylum Microsporida, in particular of the genus Nosema. Particular mention may be made of Nosema apis in the honeybee.

20

Protozoa which should be very particularly emphasized are those of the genera and species which lead to subclinical infections in pigs, in particular: Trypanosoma congolense simae, T. vivax vivax, T. congolense congolense, T. brucei evansi, Tritrichomonas suis, Trichomitus rotunda, Tetrahymenomonas buttreyi, Eimeria debbieki, E. suis, E. scabra, E. perminuta, E. spinosa, E. polita, E. porci, E. neodebbieki, Isospora suis, Cryptosporidium, Toxoplasma gondii, Sarcocystis miescheriana, S. suis hominis, Babesia trautmanni, B. perroncitoi, Balantidium coli.

25

The agricultural and breeding animals includes mammals such as, for example, cattle, horses, sheep, pigs, goats, camels, water buffalo, donkeys, rabbits, fallow deer, reindeer, fur-bearing animals such as, for example, mink, chinchilla, raccoon, birds

such as, for example, chicken, geese, turkeys, ducks, pigeons, bird species for keeping at home and in zoos. They also include useful and ornamental fish. Pigs of all species, subspecies and breeds should be particularly emphasized in this connection.

5

Laboratory and experimental animals include mice, rats, guinea pigs, golden hamsters, dogs and cats.

Pets include dogs and cats.

10

The fish include useful, breeding, aquarium and ornamental fish of all ages which live in fresh and salt water. The useful and breeding fish include, for example, carp, eel, trout, white fish, salmon, bream, roach, rudd, chub, sole, plaice, halibut, Japanese yellowtail (*Seriola quinqueradiata*), Japanese eel (*Anguilla japonica*), red sea bream (*Pagurus major*), sea bass (*Dicentrarchus labrax*), grey mullet (*Mugilus cephalus*), pompano, gilthead sea bream (*Sparus aurata*), *Tilapia* spp., chichlid species such as, for example, *plagioscion*, channel catfish. The compositions according to the invention are particularly suitable for treating fry, for example carp with a body length of from 2 to 4 cm. The compositions are also very suitable in eel growing.

15

In order that the invention may be readily understood and put into practical effect, particular preferred embodiments will now be described by way of the following, non-limiting examples.

Investigations of the efficacy of ponazuril compared with toltrazuril:

A. Efficacy of ponazuril on artificially induced infections of chickens with *Eimeria tenella*, *E. maxima* and *E. acervulina*:

5

*The aim of this investigation was to test ponazuril for efficacy for an artificial mixed infection (*Eimeria tenella*, *E. maxima* and *E. acervulina*) in chickens under cage housing conditions.*

- 10 Groups each of 44 birds (4 replicates per treatment of 11 birds in each case) were formed and, on day 14, infected with sporulated oocysts. Ponazuril was administered each day on day 10 - 24 or 17 – 24. Three dosages in the feed were used in both treatment periods: 5 ppm, 10 ppm and 20 ppm. The result of the treatment was determined by various clinical and parasitological parameters, including the mortality
15 caused by the coccidiosis and the oocyst excretion in the faeces.

20 The infection was moderate to extensive. The mortality caused by the coccidiosis was 20% of the untreated controls. It was possible to control the infection with all dosages and treatment schedules. The degree of control depended directly on the dosage and the start of the treatment. An early start of the treatment reduced the parasitological findings significantly (oocyst excretion and number of lesions) and improved the technical parameters (body weight gain and feed conversion). The highest dosage (20 mg of ponazuril in the feed) showed the best results. This dosage corresponded approximately to a dosage of 3.5 mg/kg of body weight and day.

25

B. Field trial of the efficacy of ponazuril compared with toltrazuril for the treatment of natural infections of grazing lambs with coccidiosis:

Group (infection/treatment)	Infection (parasite/route)	Treatment (formulation/ dose)	Stock (species/number/ management)	Parameter
2 groups treated with toltrazuril as drench on day 7	Infection with Eimeria spp. on the pasture (principal species E. ovinoidalis and E. crandallis)/ natural infection	5% w/v suspension, 20 mg/kg	Sheep/10 to 24 animals per group (159 sheep in total)/field trial	Oocyst excretion, mortality, consistency of the faeces, weight gain
3 groups treated with ponazuril as drench on day 7		5% w/v suspension, 10 and 20 mg/kg		
3 groups untreated				

- 5 The aim of the trials was to compare toltrazuril and ponazuril for efficacy on natural infections with pathogens of the Eimeria family.

The active ingredients were compared in three consecutive experiments:

- 10 Experiment 1: untreated control – toltrazuril 20 mg/kg – ponazuril 20 mg/kg
Experiment 2: untreated control – ponazuril 20 mg/kg
Experiment 3: untreated control – toltrazuril 20 mg/kg – ponazuril 10 mg/kg.

The oocyst excretion and the consistency of the faeces were used as main parameters.

- 15 The weight of the stock was likewise checked occasionally.

The infection pressure was low during the period of the investigation. Both toltrazuril and ponazuril were completely effective under the test conditions.

C: Efficacy of toltrazuril and ponazuril for the treatment of experimental infections of piglets with *Isospora suis*.

The aim of this trial was to investigate the efficacy of various dosages of toltrazuril and ponazuril for piglet coccidiosis.

2 groups (A and B) of 3-week old piglets were infected on day 0 by stomach tube with 5×10^3 oocysts of *Isospora suis*. Group C was kept as infected, untreated control group.

10

All the groups received toltrazuril or ponazuril as single dose according to their individual body weight on day 3 after the infection.

Group A I. toltrazuril 10 mg/kg of body weight

15

II. toltrazuril 20 mg/kg of body weight

Group B I. ponazuril 10 mg/kg of body weight

II. ponazuril 20 mg/kg of body weight

20

Group C no administration

Day			MacMaster coprological examination													
			-3	0	3	4	5	6	7	9	11	13	15	17	19	21
Group A	I.	1.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		2.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		3.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		4.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	II.	1.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		2.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		3.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		4.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Group B	I.	1.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		2.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		3.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		4.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	II.	1.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		2.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		3.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		4.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Group C	1.	-	-	-	-	-	0.2	0.3	4.8	38	72	74	78	48.8	12	
	2.	-	-	-	-	-	0.3	0.3	1.1	46	98	84.6	86	62.4	10	
	3.	-	-	-	-	-	-	0.2	1.8	57.5	102	98	88	46.8	9.6	
	4.	-	-	-	-	-	0.1	0.4	5.6	61	144	116	82.4	38.8	7.2	

Comparison of the toxicity of a sulphide (toltrazuril) with the corresponding sulphone (ponazuril):

- 5 The following toxicity data were determined in accordance with OECD/GLP guidelines, in particular OECD 414, 401 and 408. The investigations of the teratogenicity of the compounds was carried out in accordance with the US guidelines - "Teratogenicity study", Guidelines for Registering Pesticides in the U.S.A., U.S. Environmental Protection Agency, Hazard Evaluation: Human and Domestic Animals. U.S. Federal Register, Vol. 43, paragraph 163.83-3, adopted November 1982.
- 10

Investigation	Toltrazuril		Ponazuril	
	Dosage (<u>NOEL</u>)	NOEL mg/kg of body weight	Dosage (<u>NOEL</u>)	NOEL mg/kg of body weight
LD50 rat, oral	1600-5000 mg/kg of body weight	< 1000	> 5000	5000
Subchronic rat	0, <u>15</u> , 60, 240 ppm	1.1	0, 50, <u>150</u> , 250, 1000, 4000 ppm	11.2
Subchronic dog	0, <u>1.5</u> , 4.5, 13.5 mg/kg of body weight	1.5	0, <u>200</u> , 1000, 5000 ppm	8.3
Teratogenicity rat	0, <u>1</u> , 3, 10, 30 mg/kg of body weight	1.0	10, 30, <u>90</u> , 300 mg/kg of body weight	90
Teratogenicity rabbit	0, 0.5, 0.75, 1, <u>2</u> , 3, 10 mg/kg of body weight	2.0	10, <u>30</u> , 90, 300 mg/kg of body weight	30

Preparation examples

General preparation method

- 5 The suspensions indicated below can be prepared by the following methods:

The substances are each stirred together until a homogeneous suspension is produced, and the pH is adjusted to a desired range. The bentonite or sodium alginate suspension stabilizer is macerated where appropriate at about 80 or about 40°C
10 respectively. After preparation of the suspension it can be dispensed into suitable containers.

The amounts are indicated in the formulas in each case in grams [g].

15 **Example 1** (suspension)

Ponazuril microfine	10.0
Polyoxyl-35-castor oil	5.0
Methyl p-hydroxybenzoate	0.075
20 Propyl p-hydroxybenzoate	0.025
Sodium carboxymethylcellulose	1.0
Water demin.	ad 100.0 g

Example 2 (suspension)

Ponazuril microfine	1.0
Methyl p-hydroxybenzoate	0.075
Propyl p-hydroxybenzoate	0.025
Sodium alginate*	1.0
30 Water demin.	ad 100.0 g

* Macerated at 40°C

Example 3 (suspension)

	Ponazuril microfine	50.0
	Bentonite**	3.5
5	Xanthan	3.0
	Diocetyl sodium sulphosuccinate	2.5
	Simethicone emulsion	1.0
	Sodium benzoate	2.0
	Sodium propionate	2.0
10	Citric acid powder	4.0-10.0
	1,2-Propylene glycol	105.0
	Water demin.	ad 1030.0 g

The pH is adjusted to 3.4 to 4.2 by appropriate metering of citric acid.

15 ** As recommended by the manufacturer, the bentonite is preferably initially heated in aqueous suspension to 80°C and, after swelling, processed with the other ingredients to a suspension.


Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers or steps but not the exclusion of any other integer or group of integers or steps.

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgement or any form of suggestion that the prior art forms part of the common general knowledge in Australia.

Persons skilled in the art will appreciate that numerous variations and modifications will become apparent. All such variations and modifications which become apparent to persons skilled in the art, should be considered to fall within the spirit and scope that the invention broadly appearing before described.

The claims defining the invention are as follows:

1. Use of compounds of the formula (I)



5 in which

R^1 represents halogenoalkyl;

R^2 represents alkyl, alkoxy, halogen or $SO_2N(CH_3)_2$, and their physiologically tolerated salts, for controlling coccidiosis caused by *Isospora suis* in an animal.

10

2. Use of compounds according to Claim 1 for preparing anti-coccidiosis preparations.

15 3. Use according to Claim 1, wherein the compounds according to Claim 1 are administered in the form of an aqueous oral suspension.

4. Use of a compound according to Claim 1, in the manufacture of a composition, wherein the composition is an aqueous suspension, which can be administered orally.

20

5. Composition according to claim 4, wherein the composition is an aqueous suspension.

- 28 -

6. A composition comprising:
 - A) compounds of the formula (I) as defined in claim 1 in concentrations of from 0.1 to 30% by weight,
 - B) suspension stabilizers selected from bentonites and/or xanthans in concentrations each of from 0.01 to 5% by weight,
 - C) optionally ionic or nonionic wetting agents concentrations of from 0.01 to 5% by weight,
 - D) optionally antifoams based, for example, on silicones in concentrations of from 0.01 to 5% by weight
 - E) optionally humectants in concentrations of from 1 to 30% by weight,
 - F) optionally preservatives or else combinations thereof in concentrations of from 0.001 to 5% by weight,
 - G) optionally acidic or basic substances in the concentrations necessary to adjust the pH.
- 15 7. A composition according to claim 6 wherein the compounds of formula (I) are in concentrations of from 1 to 10% by weight.
8. A composition according to claim 6 or claim 7 wherein the suspension stabilizers are in concentrations of 0.05 to 1% by weight.
- 20 9. A composition according to any one of claims 6 to 8 wherein the ionic or nonionic wetting agents are in concentrations of 0.1 to 0.5% by weight.
- 25 10. A composition according to any one of claims 6 to 9 wherein the antifoams are in concentrations of 0.05 to 0.5% by weight.
11. A composition according to any one of claims 6 to 10 wherein the humectants are in concentrations from 5 to 20% by weight.

08 Mar 2007

20001278522

- 29 -

12. A composition according to any one of claims 6 to 11 wherein the preservatives or combinations thereof are in concentrations of from 0.1 to 5% by weight.
13. Method for controlling coccidiosis caused by *Isopora suis* in animals, wherein a composition comprising a compound of formula (I) as defined in Claim 1 is administered to the relevant animal.